United States Aortic Stent Grafts Market Outlook to 2033 - Abdominal Aortic Stent Grafts, Extension Pieces and Thoracic Aortic Stent Grafts
United States Aortic Stent Grafts Market Outlook to 2033 - Abdominal Aortic Stent Grafts, Extension Pieces and Thoracic Aortic Stent Grafts
Summary
GlobalData’s “United States Aortic Stent Grafts Market Outlook to 2033” is a comprehensive databook report, covering key market data on the United States Aortic Stent Grafts market. The databook report provides value (USD), volume (units) and average prices - Abdominal Aortic Stent Grafts, Extension Pieces and Thoracic Aortic Stent Grafts.
The United States Aortic Stent Grafts Market report provides key information and data on -
Annualized market revenues (USD), volume (units) and average prices (USD) data for each of the market segments. Data is provided from 2018 to 2033.
2023 company share and distribution share data for Aortic Stent Grafts Market.
Global corporate-level profiles of key companies operating within the United States Aortic Stent Grafts Market. Based on the availability of data for the particular category and country, information related to pipeline products, news and deals is also available in the report.
Scope
United States Aortic Stent Grafts is segmented as follows -
Abdominal Aortic Stent Grafts
Extension Pieces
Thoracic Aortic Stent Grafts
Reasons to Buy
The United States Aortic Stent Grafts Market report helps you to develop -
Business strategies by identifying the key market segments poised for strong growth in the future.
Market-entry and market expansion strategies.
Design competition strategies by identifying who-stands-where in the market.
Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.
Understand the key distribution channels and what’s the most preferred mode of product distribution - Identify, understand and capitalize.
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 What Is This Report About?
2.2 Aortic Stent Grafts Market Segmentation
2.3 Definitions of Markets Covered in the Report
3 Aortic Stent Grafts Market, United States
3.1 Aortic Stent Grafts Market, United States, Revenue ($m), 2018-2033
3.1.1 Extension Pieces Market, United States, Revenue ($m), by Segment, 2018-2033
3.2 Aortic Stent Grafts Market, United States, Volume (Units), 2018-2033
3.2.1 Extension Pieces Market, United States, Volume (Units), by Segment, 2018-2033
3.3 Aortic Stent Grafts Market, United States, Average Price ($), 2018-2033
3.4 Aortic Stent Grafts Market, United States, Distribution Share by Revenue ($m), 2023
3.5 Aortic Stent Grafts Market, United States, Company Share by Revenue ($m), 2023
4 Overview of Key Companies in United States, Aortic Stent Grafts Market
4.1 W. L. Gore & Associates Inc
4.1.1 Company Overview
4.2 Medtronic Plc
4.2.1 Company Overview
4.3 Cook Medical Inc
4.3.1 Company Overview
4.4 Endologix LLC
4.4.1 Company Overview
4.5 Terumo Corp
4.5.1 Company Overview
4.6 Artivion Inc
4.6.1 Company Overview
5 Aortic Stent Grafts Market Pipeline Products
6 Financial Deals Landscape
6.1 Debt Offerings
6.1.1 Merit Medical Raises USD650 Million in Private Placement of 3% Convertible Senior Notes Due 2029
6.2 Venture Financing
6.2.1 Merit Medicine System Raises USD2 Million in Seed Financing
7 Recent Developments
7.1 Corporate Communications
7.1.1 Feb 16, 2024: Jim Robo, Former Chairman and CEO of NextEra Energy, to Join Mayo Clinic Board of Trustees
7.1.2 Dec 18, 2023: Merit Medical Announces Process for Chief Executive Officer Succession Planning
7.1.3 Sep 29, 2023: Barry Slowey Named Vice President and Chief Sustainability Officer
7.1.4 Sep 15, 2023: Amber Beauchamp Named Vice President of Global Human Resources
7.1.5 Aug 24, 2023: Endologix Announces that Lucas Buchanan Joins Board of Directors
7.1.6 Aug 11, 2023: Kristin Peck, CEO of Zoetis, to join Mayo Clinic Board of Trustees
7.2 Financial Announcements
7.2.1 Feb 28, 2024: Merit Medical Introduces 'Continued Growth Initiatives' Program and Financial Targets for Three-Year Period Ending December 31, 2026
7.2.2 Jan 31, 2024: Boston Scientific Announces Results for Fourth Quarter and Full Year 2023
7.2.3 Jan 05, 2024: Boston Scientific Announces Conference Call Discussing Fourth Quarter 2023 Results
7.2.4 Dec 12, 2023: ZimVie Announces Compatibility Between its Vital Spinal Fixation System and Brainlab Spine & Trauma Navigation
7.2.5 Oct 26, 2023: Boston Scientific Announces Results for Third Quarter 2023
7.2.7 Sep 28, 2023: Coave Therapeutics to Present at Upcoming Conferences
7.2.6 Oct 18, 2023: Abbott Reports Third-Quarter 2023 Results and Raises Midpoint of Full-Year EPS Guidance Range
7.3 Government and Public Interest
7.3.1 May 21, 2024: FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics
7.3.2 Mar 14, 2024: Endologix to Present at Upcoming LSI US ’24 Emerging Medtech Summit
7.3.3 Oct 23, 2023: Sumitomo Pharma Announces Authorization in Canada of ORGOVYX for the Treatment of Men with Advanced Prostate Cancer
7.3.4 Aug 11, 2023: W. L. Gore & Associates to Present New Mosa Paper At Gvsets Conference
7.4 Legal And Regulatory
7.4.1 Feb 29, 2024: Megadyne Reiterates Intended Use Population Change for Megadyne Mega Soft Universal and Universal Plus Patient Return Electrodes
7.4.2 Jul 25, 2023: Eagle Pharmaceuticals randomises patients in pneumonia drug trial
7.5 Other Significant Developments
7.5.1 May 24, 2024: iHealthScreen Developed and Validated Risk Prediction Models for Cardiovascular Diseases Using Individual’s Retinal Color Images and Health Data
7.6 Product News
7.6.1 Dec 15, 2023: Strukmyer Receives 510(K) Clearance For Comatryx Dressing - OTC